Beyondspring Pharmaceuticals, Inc.
2 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
Recorded under 3 name spellings.
2
Ending by 2030
Jan 2029
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Jan 23, 2027The maintenance fee for Method of Treating a Brain Tumor (US 10,357,491) comes due Jan 23, 2027. Unpaid by Jul 23, 2027, it lapses early.
- 1 fee due Apr 17, 2027The maintenance fee for Composition and method for reducing thrombocytopenia (US 11,786,523) comes due Apr 17, 2027. Unpaid by Oct 18, 2027, it lapses early.
- 1 fee due Jul 2, 2027The maintenance fee for Compositions containing tucaresol or its analogs (US 11,857,522) comes due Jul 2, 2027. Unpaid by Jan 3, 2028, it lapses early.
- 1 fee due Sep 5, 2027The maintenance fee for Method of treating cancer associated with a RAS mutation (US 11,918,574) comes due Sep 5, 2027. Unpaid by Mar 6, 2028, it lapses early.
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,129,527 | Analogs of Dehydrophenylahistins and Their Theapeutic Use In force · High confidence | In force | High confidence | |
| US 7,732,605 | Synthesis of Diketopiperazines In force · High confidence | In force | High confidence | |
| US 10,076,518 | Method of Treating a Brain Tumor In force · High confidence | In force | High confidence | |
| US 10,238,650 | Method of treating cancer associated with a RAS mutation In force · From the USPTO record | In force | From the USPTO record | |
| US 10,357,491 | Method of Treating a Brain Tumor In force · High confidence | In force | High confidence | |
| US 10,668,063 | Method of treating cancer associated with a RAS mutation In force · From the USPTO record | In force | From the USPTO record | |
| US 11,045,467 | Method of treating cancer associated with a RAS mutation In force · From the USPTO record | In force | From the USPTO record | |
| US 10,155,748 | Plinabulin Compositions In force · High confidence | In force | High confidence | |
| US 11,254,657 | Plinabulin Compositions In force · High confidence | In force | High confidence | |
| US 12,024,501 | Plinabulin Compositions In force · High confidence | In force | High confidence |
Also on record, not counted in the 21: 2 patents in force now held by others · 11 ended at full term. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
3 pending · 3 abandoned · 9 no status recorded